| Drug Type Bispecific T-cell Engager (BiTE) | 
| Synonyms- | 
| Target | 
| Action stimulants, inhibitors | 
| Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EpCAM inhibitors(Epithelial cell adhesion molecule inhibitors), Immunostimulants | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Ascites | Phase 1 | - | - | |
| Kidney Neoplasms | Phase 1 | Netherlands  | - | |
| Malignant ascites | Phase 1 | Netherlands  | - | |
| Malignant Pleural Effusion | Phase 1 | - | - | |
| Pleural Effusion | Phase 1 | Netherlands  | - | |
| Renal Cell Carcinoma | Phase 1 | - | - | 






